Acquisition Opportunity CyberHeart was acquired by Varian Medical Systems in May 2019, indicating integration with a larger medical device ecosystem. Potential sales angle: align offerings with Varian’s distribution channels and post-acquisition product roadmaps to support synergistic adoption in radiation-based cardiac arrhythmia treatments.

Outpatient Focus The company targets minimally invasive, outpatient treatment using radiation delivered through CyberKnife systems. Sales approach: emphasize compatibility with outpatient workflows, reduced hospital stay costs, and rapid patient throughput to hospitals and clinics adopting radiation-based solutions.

Early Stage Revenue Current revenue is below one million with substantial funding ($25M). This suggests a growth phase with willingness to invest in product enhancement, clinical validation, and market expansion. Opportunity to propose advanced imaging, planning software, and regulatory support services to accelerate scale.

Smaller Player Dynamics Employee base of 2-10 positions CyberHeart as a nimble innovator with potential to partner with larger OEMs and service providers. Target collaborations with major medical device players to co-develop, validate, and commercialize radiation-based arrhythmia therapies through their established sales networks.

Strategic Fit The technology stack includes integration with radiation delivery platforms; potential buyers and partners include large-scale electrophysiology and cardiology device companies. Focus on offering modular hardware/software integrations, training, and support bundles that complement existing product families in the medical device market.